Vigil Neuroscience
Biotechnology, 1 Broadway Fl 7 Ste 07-300, Watertown, Massachusetts, 02142, United States, 51-200 Employees
Phone Number: 18*********
Who is VIGIL NEUROSCIENCE
Vigil Neuroscience is a clinical-stage biotechnology company focused on developing treatments for both rare and common neurodegenerative diseases by restoring the vigilance of microglia, ...
Read More
-
Headquarters: 1 Broadway Fl 7 Ste 07-300, Watertown, Massachusetts, 02142, United States
-
Date Founded: 2020
-
Employees: 51-200
-
Revenue: $10 Million to $25 Million
-
Active Tech Stack: See technologies
Industry: Biotechnology
SIC Code: 2836
|
NAICS Code: 325414 |
Show More
Does something look wrong? Fix it. | View contact records from VIGIL NEUROSCIENCE
Vigil Neuroscience Org Chart and Mapping
Email
Phone
Sign in to CIENCE GO Data to uncover contact details
Free credits every month
Frequently Asked Questions Regarding Vigil Neuroscience
Answer: Vigil Neuroscience's headquarters are located at 1 Broadway Fl 7 Ste 07-300, Watertown, Massachusetts, 02142, United States
Answer: Vigil Neuroscience's phone number is 18*********
Answer: Vigil Neuroscience's official website is https://vigilneuro.com
Answer: Vigil Neuroscience's revenue is $10 Million to $25 Million
Answer: Vigil Neuroscience's SIC: 2836
Answer: Vigil Neuroscience's NAICS: 325414
Answer: Vigil Neuroscience has 51-200 employees
Answer: Vigil Neuroscience is in Biotechnology
Answer: Vigil Neuroscience contact info: Phone number: 18********* Website: https://vigilneuro.com
Answer: Vigil Neuroscience is a clinical-stage biotechnology company focused on developing treatments for both rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. We are utilizing the tools of modern neuroscience drug development across multiple therapeutic modalities in our efforts to develop precision-based therapies to improve the lives of patients and their families. VGL101, our lead clinical candidate, is a fully human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 (TREM2) in people with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease. We are also developing VG-3927, a novel small molecule TREM2 agonist, to treat common neurodegenerative diseases associated with microglial dysfunction, with an initial focus on Alzheimers disease (AD) in genetically defined subpopulations.
Premium Sales Data for Prospecting
-
Sales data across over 200M records
-
Up-to-date records (less decayed data)
-
Accurate Email Lists (real-world tested)
-
Powerful search engine and intuitive interface
Get Full Access
Sign in to CIENCE GO Data to uncover contact details
Free credits every month